Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib

Journal of Clinical Gastroenterology

Volumn 45, Issue 8, 2011, Pages 733-737

  Frenette, Catherine T ^a   Frederick, Richard Todd ^a   Gish, Robert G ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

hand foot skin reaction; hepatocellular carcinoma; sorafenib

Indexed keywords

ALPHA FETOPROTEIN; ATROPINE PLUS DIPHENOXYLATE; CISPLATIN; CLOBETASOL; DOXORUBICIN; IODINATED POPPYSEED OIL; KERALAC; LIDOCAINE; LOPERAMIDE; MITOMYCIN; PHOSPHATE; PROTON PUMP INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG; UREA;

AGED; ARTICLE; BLEEDING; BLOATING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHEMOEMBOLIZATION; CLINICAL PROTOCOL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG USE; DYSPEPSIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; LOTION; MALE; PATIENT ASSESSMENT; PRESCRIPTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; FATAL OUTCOME; FEMALE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; PYRIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 80052028786     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181f68e83     Document Type: Article

References (20)

1. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer. 1985;56:918-928. (Pubitemid 15228292)
2. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008; 134:1752-1763. (Pubitemid 351615415)
3. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524. (Pubitemid 34183954)
4. Nexavar [prescribing information]. Available at: http://www. univgraph.com/bayer/inserts/nexavar.pdf. Accessed October 16, 2009.
5. Llovet J, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
6. Cheng A, Kang Y, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: results of a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10: 25-34.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208-1236. (Pubitemid 43112690)
8. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225-235. (Pubitemid 40613379)
9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers v.2. 2009 [data file] [2]. 2009.
10. Anderson R, Jatoi A, Robert C, et al. Search for evidencebased approaches for the prevention and palliation of handfoot skin reaction (HFSR) caused by the multikinase inhibitors (MKI). Oncologist. 2009;14:291-302.
11. Chu D, Lacouture ME, Fillos T, et al. Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47:176-186.
12. Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9:117-123.
13. Chang YS, Adnane J, Trail PA, et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574. (Pubitemid 46295136)
14. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64: 7099-7109. (Pubitemid 39331023)
15. Margulis V, Matin SF, Tannir N, et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol. 2008;180:94-98.
16. Je Y, Schutz FAB, Choueiri TK. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol. 2009;10:967-974.
17. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl. 2004;10:534-540. (Pubitemid 38443593)
18. Marsh JW, Dvorchik I, Subotin M, et al. The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology. 1997;26:444-450. (Pubitemid 27328324)
19. Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant. 2009;9:2851-2854.
20. Chen Z, Yu S, Guan Z, et al. Efficacy and safety of sorafenib in patients from the Asia-Pacific (AP) region with advanced hepatocellular carcinoma (HCC): impact of prior transarterial chemoembolization and transarterial embolization (TACE/ TAE). Presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases; Oct 30-Nov 3, 2009; Boston, MA.